ChemotherapyFDA-approvedFirst-line
Folfox
Generic name: oxaliplatin
How it works
Interferes with DNA replication in cancer cells, causing cell death. Oxaliplatin is a platinum-based chemotherapy agent.
Cancer types
Colorectal Cancer— All patients
Efficacy
In clinical trials, Folfox chemotherapy regimens improved median overall survival by approximately 6 months compared to 5-fluorouracil/leucovorin alone.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| New Treatment Combination Shows Promise for Colon Cancer Patients | Colorectal Cancer | phase-3 | The 3-year disease-free survival was 86.3% in the atezolizumab-mFOLFOX6 group, as compared with 76.2% in the mFOLFOX6 group. | Source → |
| Nicotine Affects Colon Cancer Treatment Efficacy | Colorectal Cancer | lab-study | — | Source → |
| New Diagnostic Tool for Colorectal Cancer Identified | Colorectal Cancer | lab-study | The diagnostic signature demonstrated robust performance in distinguishing resistant cases (AUC = 0.868). | Source → |
| Comparing Second-Line Treatments for Pancreatic Cancer | Pancreatic Cancer | observational | 5-FU + Nal-IRI showed a median overall survival of 7.2 months, compared to 5.8 months for FOLFOX/XELOX. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.